Simcere has been continuously expanding its R&D investments. In 2021, its R&D investment was more than CNY 1.4 billion, accounting for 28.3% of the sales revenue.
With four R&D centers in Shanghai, Nanjing, Beijing and Boston, the company has established a whole-process R&D system integrating drug discovery, pre-clinical development, clinical trials, and drug registration, owns a R&D pipeline project of nearly 60 new drugs, and is conducting 22 clinical studies for registration of 19 potential innovative drugs.

R&D Pipeline

We have nearly 60 innovative product candidates in different stages of development, among which over 10 product candidates had obtained the IND approval or were at clinical stage.

MORE+

State Key Laboratory

Simcere was approved by the Ministry of Science and Technology of the PRC in October 2015 to establish the only state key laboratory of translational medicine and innovative pharmaceuticals in the PRC pharmaceutical industry. Since its establishment, we have made rapid progress in critical technologies breakthroughs, new drug development, talent training and team building.
This laboratory focuses on the translational medicine and precision medicine-based research and development of innovative pharmaceuticals for the treatment of oncology, central nervous system diseases, autoimmune diseases and infectious diseases.
The laboratory’s several goals include establishing key translational medicine technologies for new drug development, creating an integrated platform for general translational medicine technology research, and providing exemplary models of platform setup (including required key technologies) and industry standards for new drug development within translational medicine.

Boston R&D Center Massachusetts is home to 19% of the top pharmaceutical product pipelines in the United States and 9% globally. The state capital, Boston, in particular holds a dominating position in the global life sciences community. Simcere’s Boston R&D Center focuses on the world's cutting-edge cell and gene therapies, and with its team of pioneering scientists, it remains dedicated to building a world-class R&D center. Utilizing the world's state-of-the-art technologies, we are rapidly building several cutting-edge technology platforms for cell and gene therapies and thereby making the Boston R&D Center a powerful pipeline driver for Simcere through the institute’s fast and efficient project promotion system.

Global R&D Center Layout

Boston R&D Center

Nanjing R&D Center

Shanghai R&D Center

R&D Pipeline

State Key Laboratory

Boston R&D Center